<?xml version='1.0' encoding='utf-8'?>
<document id="23328267"><sentence text="Rivaroxaban: an oral factor Xa inhibitor."><entity charOffset="0-11" id="DDI-PubMed.23328267.s1.e0" text="Rivaroxaban" /></sentence><sentence text="Currently available anticoagulants utilized for venous thromboembolism (VTE) treatment and prevention and stroke prevention in patients with atrial fibrillation (AF) have proven effectiveness but are not optimally utilized because of barriers such as the need for subcutaneous administration and requisite routine laboratory monitoring" /><sentence text=" Rivaroxaban, a novel oral Xa inhibitor, is an alternative to standard therapies utilized for VTE prevention after elective orthopedic surgery, primary and secondary stroke prevention in nonvalvular AF, VTE treatment after an acute VTE event, and secondary prevention after the acute coronary syndromes (ACS)"><entity charOffset="1-12" id="DDI-PubMed.23328267.s3.e0" text="Rivaroxaban" /></sentence><sentence text="" /><sentence text="This article reviews the pharmacology, efficacy, and tolerability of rivaroxaban for VTE prophylaxis in post-orthopedic surgery and medically ill patients, stroke prevention in nonvalvular AF, adjunctive therapy in patients with ACS, and VTE treatment"><entity charOffset="69-80" id="DDI-PubMed.23328267.s5.e0" text="rivaroxaban" /><entity charOffset="229-232" id="DDI-PubMed.23328267.s5.e1" text="ACS" /><pair ddi="false" e1="DDI-PubMed.23328267.s5.e0" e2="DDI-PubMed.23328267.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23328267.s5.e0" e2="DDI-PubMed.23328267.s5.e1" /></sentence><sentence text="" /><sentence text="International Pharmaceutical Abstracts and EMBASE were searched for English-only clinical trials and reviews published between 1970 and March 15, 2012" /><sentence text=" PubMed was searched for articles published between 1970 and June 30, 2012" /><sentence text=" Additional trials and reviews were identified from the citations of published articles" /><sentence text="" /><sentence text="Eighty-nine publications were identified: 10 clinical trials and 1 meta-analysis were used to obtain efficacy and tolerability data, and 1 analysis of pooled data from the clinical trials was included; 17 pharmacokinetic, pharmacodynamic, and drug-drug interaction studies were included; and 5 cost-analyses were reviewed" /><sentence text=" These data showed rivaroxaban to be noninferior to enoxaparin for thromboprophylaxis of VTE after total knee and total hip replacement surgery"><entity charOffset="19-30" id="DDI-PubMed.23328267.s12.e0" text="rivaroxaban" /><entity charOffset="52-62" id="DDI-PubMed.23328267.s12.e1" text="enoxaparin" /><pair ddi="false" e1="DDI-PubMed.23328267.s12.e0" e2="DDI-PubMed.23328267.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23328267.s12.e0" e2="DDI-PubMed.23328267.s12.e1" /></sentence><sentence text=" It was also shown to be noninferior to vitamin K antagonist therapy for primary and recurrent stroke prevention in nonvalvular AF as well as for the treatment of VTE after an acute deep vein thrombosis or pulmonary embolism"><entity charOffset="40-49" id="DDI-PubMed.23328267.s13.e0" text="vitamin K" /></sentence><sentence text=" It also showed benefit in lowering the risk for major adverse cardiovascular events after ACS"><entity charOffset="91-99" id="DDI-PubMed.23328267.s14.e0" text="ACS" /></sentence><sentence text=" Differences in major bleeding rates were not statistically significant between rivaroxaban and comparators across the various studies, with the exception of ACS, in which there were higher rates of non-coronary artery bypass graft surgery related bleeding and intracranial hemorrhage"><entity charOffset="80-91" id="DDI-PubMed.23328267.s15.e0" text="rivaroxaban" /><entity charOffset="158-168" id="DDI-PubMed.23328267.s15.e1" text="ACS" /><pair ddi="false" e1="DDI-PubMed.23328267.s15.e0" e2="DDI-PubMed.23328267.s15.e0" /><pair ddi="false" e1="DDI-PubMed.23328267.s15.e0" e2="DDI-PubMed.23328267.s15.e1" /></sentence><sentence text="" /><sentence text="Based on the findings of the studies reported in this review, rivaroxaban is an effective option for the prevention of VTE after orthopedic surgery, stroke prevention for nonvalvular AF, and treatment of VTE"><entity charOffset="62-73" id="DDI-PubMed.23328267.s17.e0" text="rivaroxaban" /></sentence><sentence text=" At this time, rivaroxaban cannot be recommended for secondary risk reduction after ACS because of the increased bleeding risk"><entity charOffset="15-26" id="DDI-PubMed.23328267.s18.e0" text="rivaroxaban" /><entity charOffset="84-94" id="DDI-PubMed.23328267.s18.e1" text="ACS" /><pair ddi="false" e1="DDI-PubMed.23328267.s18.e0" e2="DDI-PubMed.23328267.s18.e0" /><pair ddi="false" e1="DDI-PubMed.23328267.s18.e0" e2="DDI-PubMed.23328267.s18.e1" /></sentence><sentence text="" /></document>